This marks Revelation Biosciences’ third reverse stock split over the past year. ・Last week, the company said it would exercise outstanding warrants to purchase up to 13.1 million shares for gross ...

Revelation Biosciences (NASDAQ:REVB) is a life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has multiple product ...

The average one-year price target for Revelation Biosciences (NasdaqCM:REVB) has been revised to $86.70 / share. This is an increase of 300.00% from the prior estimate of $21.68 dated January 11, 2026 ...

Revelation Biosciences (NASDAQ:REVB) is a life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has multiple product ...

Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in ...

Revelation Biosciences Inc. (NASDAQ: REVB) surged 25.22% in after-hours trading to $1.07 on Thursday after the company announced it reached agreement with the Food and Drug Administration on an ...

Revolution Beauty (LON: REVB) shares are down a little bit, 3%, on the news that they really are going after those responsible for the company’s recent problems. However, unlike those rumours over the ...

Revolution Beauty (LON: REVB) has released an update to its past accounts. REVB has been suspended since autumn last year of course over these very accounts. This Revolution Beauty release is ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

The average one-year price target for Revelation Biosciences (NasdaqCM:REVB) has been revised to $86.70 / share. This is an increase of 300.00% from the prior estimate of $21.68 dated January 11, 2026 ...